Vir Biotechnology, Inc. (VIR) financial statements and ratios from SEC XBRL: revenue $68.56M (TTM), net margin -638.9%, revenue growth -101.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $68.56M |
| Net Margin | -638.9% |
| Revenue Growth (YoY) | -101.0% |
| EPS Growth (YoY) | -3.4% |
| FCF Growth (YoY) | 66.5% |
| Price / Book | 1.91 |
| Price / Sales | 23.74 |
| FCF Yield | -28.9% |
| Altman Z-Score | 0.57 (distress) |
| Sector P/E (Healthcare) | 21.6 |
VIR overview · VIR earnings · VIR KPIs · VIR investor relations · VIR ownership · VIR peers · VIR filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.